Covista

CVSA · NYSE

$127.64−$0.94 (−0.73%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $128.58

CVSA analyst rating

BuyConsensus of 3 analysts over the last 12 months. 67% rate it a buy.

Strong buy0
Buy2
Hold1
Underperform0
Sell0

12-month price target · 6 analysts

Average $162.69 (+27.5% upside)

Low: $141.40
Now: $127.64
High: $183.75

Upgrades and downgrades

The latest rating actions, newest first

CVSA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
BMO Capital	Oct 5, 2026	Maintains	Outperform	$148.00 → $145.00	60%
Truist Securities	Sep 3, 2026	Downgrade	Buy → Hold	$140.00	63%
Barrington Research	Jun 8, 2026	Maintains	Outperform	$170.00	63%
Truist Securities	May 11, 2026	Maintains	Buy	$130.00 → $140.00	63%
Barrington Research	Apr 17, 2026	Maintains	Outperform	$170.00	63%
Truist Securities	Mar 24, 2026	Initiates	Buy	$130.00	63%
Barrington Research	Mar 2, 2026	Maintains	Outperform	$170.00	63%

The case for and against

Updated Oct 14, 2026

Bull case

Covista is supported by improving fundamentals at Chamberlain, where enrollment returned to 0.5% y/y growth to 40.8k one quarter early, aided by two straight quarters of double-digit application growth, normalized conversion, and persistent pre-licensure expansion. The company also posted strong profitability, with adj. EBITDA of $128M versus $117M consensus and adj. EPS of $1.98, while management raised revenue guidance to $1.93B-$1.945B and expects about 100bps of EBITDA margin expansion. With Walden still the largest revenue driver, domestic operations dominant, and net leverage only 0.7x, the firm appears well positioned to compound earnings through favorable healthcare and veterinary demand plus a disciplined but flexible capital allocation strategy.

Bear case

Covista is facing a negative outlook despite a clean F3Q beat because the fundamental setup still carries several structural risks, including a further slowdown in new starts at Chamberlain and the possibility of missing recently issued long-term financial targets. While total revenues rose 5% y/y to $487M, the gains were concentrated in Walden at $187M and Chamberlain at $197M, leaving the business exposed to uneven demand trends and dependence on domestic operations. The company also faces regulatory overhang, possible increases in claims tied to legacy DeVry ownership, and political risk from unfavorable Education Department changes, all of which could pressure future execution and sentiment.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.